TCR2 THERAPEUTICS INC (TCRR) Stock Analyst Ratings
NASDAQ:TCRR - Nasdaq - US87808K1060 - Common Stock - Currency: USD
ChartMill assigns a Buy % Consensus number of 73% to TCRR. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 5.86. This target is 295.87% above the current price.
TCRR was analyzed by 12 analysts. The buy percentage consensus is at 73. So analysts seem to be have mildly positive about TCRR.
In the previous month the buy percentage consensus was at a similar level.
TCRR was analyzed by 12 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2023-03-24 | Mizuho | Downgrade | Buy -> Neutral |
| 2023-03-23 | EF Hutton | Reiterate | Hold |
| 2023-03-09 | Jefferies | Downgrade | Buy -> Underperform |
| 2023-03-08 | Truist Securities | Downgrade | Buy -> Hold |
| 2023-03-07 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2023-01-06 | Piper Sandler | Maintains | Overweight |
| 2023-01-05 | EF Hutton | Initiate | Hold |
| 2022-11-21 | HC Wainwright & Co. | Maintains | Buy |
| 2022-11-08 | SVB Leerink | Maintains | Market Perform |
| 2022-05-19 | HC Wainwright & Co. | Maintains | Buy |
| 2022-01-19 | Goldman Sachs | Downgrade | Buy -> Neutral |
| 2022-01-13 | HC Wainwright & Co. | Maintains | Buy |
| 2021-11-10 | SVB Leerink | Maintains | Market Perform |
| 2021-10-21 | SVB Leerink | Downgrade | Outperform -> Market Perform |
| 2021-09-20 | Truist Securities | Maintains | Buy |
| 2021-09-20 | HC Wainwright & Co. | Maintains | Buy |
| 2021-08-06 | SVB Leerink | Maintains | Outperform |
| 2021-06-24 | Goldman Sachs | Initiate | Buy |
| 2021-03-11 | SVB Leerink | Maintains | Outperform |